- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03181841
Effects of PF-06412562 on Value-based Decision-making in Healthy Individuals
Effects of PF-06412562 on Value-based Decision-making in Healthy Individuals: a Mono-center, Randomized, Placebo Controlled, Double-blind Study (Phase I)
Numerous psychiatric and neurodegenerative diseases like schizophrenia, dependency on drugs of abuse, depression and Parkinson's disease are related to motivational and cognitive deficits in value-based decision making, which frequently persist even after a successful pharmacological treatment. According to current neurobiologic models, cortical dopamine D1 receptors play a crucial role in taking value-based decisions. In this study, it will be investigated whether value-based decisions in healthy volunteers can be improved by stimulation of D1-receptors. For this purpose, a newly developed dopamine D1-agonist will be used, which selectively increases the activities of frontal D1- and D5-receptors. In this double-blind, randomized, placebo-controlled study, the effects of different single doses of PF-06412562, a not yet licensed D1-agonist, on value-based decision making will be compared with placebo. The use of different dosage strengths will allow to investigate a potential relationship between the extent of activity of the D1-receptor and its influence on behavioral indices.
Therefore, four parallel groups will be investigated. Each participant takes in a single dose of either PF-06412562 in different doses or placebo. A screening exam will be carried out 1-3 weeks before the drug intake, and a follow-up examination will be carried out approx. 1 week after the drug intake. At all 3 visits in the study centre, several tests for the investigation of value-based decision making will be carried out.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Zurich, Switzerland, CH-8091
- University Hospital Zurich, Dept. of Clinical Pharmacology and Toxicology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Informed Consent as documented by signature on the informed consent form
- Physically and psychiatrically healthy men and women
- Male and female subjects of childbearing potential must agree to use a highly effective method of contraception throughout the study and for at least 28 days for females and 90 days for males after the last dose of assigned treatment. A subject is of childbearing potential if, in the opinion of the investigator, he/she is biologically capable of having children.
Female subjects of non childbearing potential must meet at least one of the following criteria:
- Have undergone a documented hysterectomy and/or bilateral oophorectomy;
- Have medically confirmed ovarian failure or;
- Achieved post menopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; and have a serum follicle stimulating hormone (FSH) level confirming the post menopausal state.
- All other female subjects (including females with tubal ligations and females that do NOT have a documented hysterectomy, bilateral oophorectomy and/or ovarian failure) will be considered to be of childbearing potential.
- Aged 18-35 years
- Negative pregnancy test (see exclusion criteria)
- Normal or corrected-to-normal vision
Exclusion Criteria (selected):
- Pregnant female subjects; breastfeeding female subjects
- considered to be healthy based on an extensive pre-study screening including anamnesis, physical examination, laboratory investigations, vital signs, ECG, etc.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Single dose of placebo
|
double-blind oral intake of single doses of the aforementioned drug or placebo
|
Experimental: Active dose 1
Single dose of PF-06412562 in low dosage strength
|
double-blind oral intake of single doses of the aforementioned drug or placebo
|
Experimental: Active dose 2
Single dose of PF-06412562 in medium dosage strength
|
double-blind oral intake of single doses of the aforementioned drug or placebo
|
Experimental: Active dose 3
Single dose of PF-06412562 in higher dosage strength
|
double-blind oral intake of single doses of the aforementioned drug or placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in a delay discounting task.
Time Frame: 1-3 weeks before (= baseline), 5 hours after, and approx. 1 week after drug intake.
|
This validated computer-based decision-making test will be filled in by each participant at three time points during the study: 1-3 weeks before, 5 hours after, and approx. 1 week after a single oral intake of 1 out of 3 possible doses of PF-06412562, or matching placebo.
|
1-3 weeks before (= baseline), 5 hours after, and approx. 1 week after drug intake.
|
Change from baseline in a risk discounting task.
Time Frame: 1-3 weeks before (= baseline), 5 hours after, and approx. 1 week after drug intake.
|
This validated computer-based decision-making test will be filled in by each participant at three time points during the study: 1-3 weeks before, 5 hours after, and approx. 1 week after a single oral intake of 1 out of 3 possible doses of PF-06412562, or matching placebo.
It will be carried out after the test for outcome 1.
|
1-3 weeks before (= baseline), 5 hours after, and approx. 1 week after drug intake.
|
Effect of PF-06412562 on an effort discounting task (compared to placebo).
Time Frame: 5 hours after drug intake.
|
This validated computer-based decision-making test will be completed by each participant 5 hours after a single oral intake of 1 out of 3 possible doses of PF-06412562, or matching placebo and after having completed the tests for outcome 1 and 2.
|
5 hours after drug intake.
|
Effect of PF-06412562 on the Pavlovian to instrumental transfer task (compared to placebo).
Time Frame: 5 hours after drug intake.
|
This validated computer-based decision-making task tests Pavlovian acquisition and transfer.
It will be carried out by each participant immediately after the test in outcome 3.
|
5 hours after drug intake.
|
Effect of PF-06412562 on an exploration / exploitation task (compared to placebo).
Time Frame: 5 hours after drug intake.
|
This validated computer-based decision-making task tests different aspects of value-based decision making.
It will be carried out by each participant immediately after the test in outcome 4.
|
5 hours after drug intake.
|
Effect of PF-06412562 on a probabilistic reversal learning task (compared to placebo).
Time Frame: 5 hours after drug intake.
|
This validated computer-based decision-making task tests different aspects of value-based decision making.
It will be carried out by each participant immediately after the test in outcome 5.
|
5 hours after drug intake.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of treatment-emergent adverse events (safety and tolerability of PF-06412562)
Time Frame: throughout the study and up to 1 week after study drug intake.
|
continuous assessment of adverse events by non-leading questions, repeated safety laboratory tests, repeated ECGs, repeated control of vital parameters.
|
throughout the study and up to 1 week after study drug intake.
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Plasma concentrations of PF-06412562
Time Frame: blood sampling 4 hours and 8 hours after the study drug intake.
|
blood sampling 4 hours and 8 hours after the study drug intake.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Philippe Tobler, Prof. Dr., University of Zurich, Dept. of Economics
- Principal Investigator: Alexander Jetter, MD, University of Zurich
Publications and helpful links
General Publications
- Soutschek A, Gvozdanovic G, Kozak R, Duvvuri S, de Martinis N, Harel B, Gray DL, Fehr E, Jetter A, Tobler PN. Dopaminergic D1 Receptor Stimulation Affects Effort and Risk Preferences. Biol Psychiatry. 2020 Apr 1;87(7):678-685. doi: 10.1016/j.biopsych.2019.09.002. Epub 2019 Sep 12.
- Soutschek A, Kozak R, de Martinis N, Howe W, Burke CJ, Fehr E, Jetter A, Tobler PN. Activation of D1 receptors affects human reactivity and flexibility to valued cues. Neuropsychopharmacology. 2020 Apr;45(5):780-785. doi: 10.1038/s41386-020-0617-z. Epub 2020 Jan 21.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- PHA-16-D1AGO-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Decision Making
-
Massachusetts General HospitalUnknownDecision Making | Video Decision AidsUnited States
-
Boston CollegeCompleted
-
Instituto Tecnologico y de Estudios Superiores...Completed
-
Brigham and Women's HospitalCompleted
-
University Hospital, Clermont-FerrandCompleted
-
Umraniye Education and Research HospitalCompleted
-
University of UtahNational Institutes of Health (NIH)Completed
-
University of PittsburghRecruiting
-
National Human Genome Research Institute (NHGRI)Completed
-
Taipei Medical University Shuang Ho HospitalChi Mei Medical HospitalCompletedDecision Making, SharedTaiwan
Clinical Trials on PF-06412562
-
PfizerTerminated
-
PfizerCompletedSchizophreniaUnited States
-
PfizerCompleted
-
Yale UniversityNational Institute of Mental Health (NIMH); University of Pennsylvania; Columbia... and other collaboratorsRecruitingEarly Course Schizophrenia Spectrum DisorderUnited States
-
PfizerCompletedParkinson's DiseaseUnited States
-
InvicroCompletedHealthy Male VolunteersUnited States
-
PfizerCompleted
-
Milton S. Hershey Medical CenterPfizerCompleted